Type-level market taxonomy breaks the Achalasia Treatment market into intervention technologies that compete on safety, durability, and reimbursement. Oral Pharmacotherapyโmainly nitrates, PDE-5 inhibitors, and PPIsโcaptures the largest patient pool yet contributes <10 % of market value because generic pricing erodes revenue; its role is temporizing, preserving share in cost-sensitive regions. End-guided Pneumatic Dilation (PD) sits at ~40 % of revenues: reusable inflation devices plus high-cost 30โ35 mm balloons yield a mid-four-figure procedure with repeat potential every 3โ5 years, making PD the economic anchor for device firms. Surgical Myotomyโlaparoscopic Heller plus partial fundoplicationโgenerates โ35 %, leveraging OR pack pricing and higher payer reimbursement despite declining volumes. Finally, Botulinum Toxin Injections, though priced <$500 per session, claim โ15 % as a bridge therapy for elderly co-morbid patients, with repeat cycles sustaining steady cash flow. Collectively, these modalities map clinical efficacy to procurement budgets, anchoring forecast models for Achalasia Treatment segmentation.